Search results
Results from the WOW.Com Content Network
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. [2] [3] [5] It bispecifically binds CD20 and CD3 to engage T-cells. [2] [3] It was developed by Genentech. [6] The most common adverse reactions (≥20%) include cytokine release syndrome, fatigue, rash, pyrexia, and headache.
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed
Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. [4] [7] Epcoritamab is a bispecific CD20-directed CD3 T-cell engager.
The most common side effects of Journavx, according to the company’s website, include itching, muscle spasms, rash, and increased levels of an enzyme called creatine phosphokinase in the blood ...
Amy Schumer once hopped on board the Ozempic trend, but the side effects were so intense she had to stop. During a recent appearance on "The Howard Stern Show," the comedian, 43, opened up about ...
There are a wide range of Dutch ovens out there today, and they vary in size, material, and price. To help you find the best option to add to your kitchen, we spent months testing a total of 10 ...
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
The benefit and side effects of loncastuximab tesirine were evaluated in one clinical trial, ADCT-402-201 (LOTIS-2 / NCT03589469), that included 145 participants with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments that did not work or were no longer working.